Morning Briefing
Summaries of health policy coverage from major news organizations
Drugmaker Recalls Some Epi-Pens In U.S. And Overseas
Stat: Mylan Extends EpiPen Recall To The US And Other Countries
A widespread recall of EpiPen that began last week in several countries has now spread to the United States and parts of Europe, Asia, and North and South America due to a product defect. For the moment, it remains unclear how many allergic-reaction devices are being recalled. The effort, which Mylan described as voluntarily, began earlier this month in Australia, Denmark, Ireland, Norway, Finland, New Zealand and Japan, where tens of thousands of EpiPens were pulled. (Silverman, 3/31)
The Associated Press: Anti-Allergy Medicine EpiPen Recall Expands To US
A recall of the emergency anti-allergy medicine EpiPen is expanding to the U.S. and other markets in North America, Europe, Asia and South America because the allergy shots may not work. The notice issued Friday by Mylan N.V. expands upon warnings made earlier this month after two reports of the device failing. (3/31)
